Topline Data: Barzolvolimab Performs Well in Phase 2 CindU Study
Celldex Therapeutics, Inc.’s barzolvolimab performed well in Phase 2 clinical trial of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD), the Company reports. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and […]